Drug Profile
Research programme: hormone based therapeutics - Innopharma
Alternative Names: IP 126Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator InnoPharma Inc
- Class Hormones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Undefined in USA
- 25 Sep 2014 InnoPharma Inc has been acquired by Pfizer
- 13 Nov 2013 Preclinical trials in Undefined indication in USA (Injection, Ophthalmic)